Aberrant protein synthesis is frequently observed in cancer however a transcriptome-wide translation landscape in cancer is largely unknown. RNA binding proteins in conjunctions with regulatory RNA controls translation program in a cell type and state-specific manner. We are interested in characterizing the translational landscape in cancer and microenvironment using the advanced single-cell methodology and sequencing tools that enable us to precisely measure translation efficiency and map translation start sites. Our studies will define the “molecular basis of translation reprogramming in MYC and KRAS driven cancer and microenvironment”.Long-term goal of our research team is to study the cell type and state-specific translation programs in cancer and identify new actionable and druggable therapeutic targets based on inhibiting cancer-specific translation programs.